CD2BP2
CD2 antigen cytoplasmic tail-binding protein 2
Protein Summary
Involved in pre-mRNA splicing as component of the U5 snRNP complex that is involved in spliceosome assembly. This gene encodes a bi-functional protein. In the cytoplasm, the encoded protein binds the cytoplasmic tail of human surface antigen CD2 via its C-terminal GYF domain, and regulate CD2-triggered T lymphocyte activation. In the nucleus, this protein is a component of the U5 small nuclear ribonucleoprotein complex and is involved in RNA splicing. A pseudogene has been identified on chromosome 7. Alternative splicing results in multiple transcript variants but their biological validity has not been determined. [provided by RefSeq, Nov 2008]
- ENST00000305596
- ENSP00000304903
- ENSG00000169217
- ENST00000569466
- ENSP00000456935
- KIAA1178
- LIN1
- Snu40
- FWP010
- U5-52K
- PPP1R59
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
transcription factor binding site profile | 0.87 | ||
histone modification site profile | 0.86 | ||
kinase perturbation | 0.71 | ||
transcription factor perturbation | 0.68 | ||
microRNA | 0.67 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 85.24 (req: < 5)
Gene RIFs: 5 (req: <= 3)
Antibodies: 174 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 85.24 (req: >= 5)
Gene RIFs: 5 (req: > 3)
Antibodies: 174 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 4
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0